Wu H, Wang W, Tong S, Wu C. Nucleostemin regulates proliferation and migration of gastric most cancers and correlates with its malignancy. Int J Clin Exp Med. 2015;8:17634–43.
Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Track S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.
Harada Okay, Mizrak Kaya D, Shimodaira Y, Ajani JA. World chemotherapy growth for gastric most cancers. Gastric Most cancers. 2017;20:92–101.
Reisman D, Glaros S, Thompson EA. The SWI/SNF complicated and most cancers. Oncogene. 2009;28:1653–68.
Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic evaluation of mammalian SWI/SNF complexes identifies in depth roles in human malignancy. Nat Genet. 2013;45:592–601.
Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153:71–85.
Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes throughout oncogenic transformation. Most cancers Cell. 2010;18:316–28.
McBride MJ, Pulice JL, Beird HC, Ingram DR, D’Avino AR, Shern JF, et al. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complicated Focusing on and Perform to Drive Synovial Sarcoma. Most cancers Cell. 2018;33:1128–41.e7.
Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin reworking genes. Nat Genet. 2012;44:570–4.
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular evaluation of gastric most cancers identifies subtypes related to distinct scientific outcomes. Nat Med. 2015;21:449–56.
Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Complete molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
Li J, Wang W, Zhang Y, Cieślik M, Guo J, Tan M, et al. Epigenetic driver mutations in ARID1A form most cancers immune phenotype and immunotherapy. J Clin Make investments. 2020;130:2712–26.
Lord CJ, Ashworth A. PARP inhibitors: Artificial lethality within the clinic. Science. 2017;355:1152–8.
Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art methods for focusing on the DNA injury response in most cancers. Nat Rev Clin Oncol. 2019;16:81–104.
Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24:556–62.
Li T, Shi L, Liu W, Hu X, Hui Y, Di M, et al. Aloe-Emodin Induces Mitochondrial Dysfunction and Pyroptosis by Activation of the Caspase-9/3/Gasdermin E Axis in HeLa Cells. Entrance Pharmacol. 2022;13:854526.
Andrikopoulou A, Chatzinikolaou S, Panourgias E, Kaparelou M, Liontos M, Dimopoulos MA, et al. The rising position of capivasertib in breast most cancers. Breast. 2022;63:157–67.
Jiang M, Qi L, Li L, Li Y. The caspase-3/GSDME sign pathway as a swap between apoptosis and pyroptosis in most cancers. Cell Dying Discov. 2020;6:112.
Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, et al. Pyroptosis: a brand new paradigm of cell demise for preventing in opposition to most cancers. J Exp Clin Most cancers Res. 2021;40:153.
Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy medication induce pyroptosis by means of caspase-3 cleavage of a gasdermin. Nature. 2017;547:99–103.
Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 throughout apoptosis mediates development to secondary necrotic/pyroptotic cell demise. Nat Commun. 2017;8:14128.
Dong S, Shi Y, Dong X, Xiao X, Qi J, Ren L, et al. Gasdermin E is required for induction of pyroptosis and extreme illness throughout enterovirus 71 an infection. J Biol Chem. 2022;298:101850.
Lee D, Yu EJ, Ham IH, Hur H, Kim YS. AKT inhibition is an efficient therapy technique in ARID1A-deficient gastric most cancers cells. Onco Targets Ther. 2017;10:4153–9.
Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci. 2013;14:18824–49.
Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and most cancers. Nat Rev Most cancers. 2011;11:481–92.
Oike T, Ogiwara H, Tominaga Y, Ito Okay, Ando O, Tsuta Okay, et al. An artificial lethality-based technique to deal with cancers harboring a genetic deficiency within the chromatin reworking issue BRG1. Most cancers Res. 2013;73:5508–18.
Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, et al. ARID1B is a particular vulnerability in ARID1A-mutant cancers. Nat Med. 2014;20:251–4.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for most cancers drug discovery. Nat Rev Drug Discov. 2005;4:988–1004.
Shaw RJ, Cantley LC. Ras, PI(3)Okay and mTOR signalling controls tumour cell progress. Nature. 2006;441:424–30.
Li L, Wang S, Zhou W. Steadiness Cell Apoptosis and Pyroptosis of Caspase-3-Activating Chemotherapy for Higher Antitumor Remedy. Cancers (Basel). 2022;15:26.
Kim YB, Ham IH, Hur H, Lee D. Numerous ARID1A expression patterns and their scientific significance in gastric cancers. Hum Pathol. 2016;49:61–70.
Chandler RL, Brennan J, Schisler JC, Serber D, Patterson C, Magnuson T. ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF. Mol Cell Biol. 2013;33:265–80.
